BD today announced plans to invest more than $35 million and add approximately 50 new jobs to expand prefilled flush syringe manufacturing at its Columbus, Nebraska facility.
The investments will support new BD PosiFlush Prefilled Flush Syringe production lines, product innovation and operational efficiencies, enabling BD to produce hundreds of millions of additional units annually to meet growing demand from U.S. hospitals and health systems.
Prefilled flush devices like PosiFlush Prefilled Flush Syringes are used as part of catheter care and maintenance to help prevent catheter-related complications. Quality in manufacturing is critical as these devices deliver fluid directly into a patient's bloodstream, where any contamination or defect can have serious, even fatal, consequences.
PosiFlush Prefilled Flush Syringes are manufactured using a fully automated, hands-free process, ensuring that the first person to touch the syringe is the clinician – helping to reduce the potential for contamination. Every syringe is inspected using a rigorous, multi-step, end-to-end inspection process to meet high quality standards for patients and providers.
Over the past three years, BD said it has invested more than $80 million to expand BD PosiFlush capacity, increasing U.S. production by more than 750 million units, including a 10% increase this year alone. The company's facility in Columbus is the largest manufacturer of prefilled flush devices in the U.S. and has been operating for more than 75 years.
BD operates more than 30 U.S. manufacturing and distribution facilities across 17 states and Puerto Rico that employ more than 10,000 people. These facilities form a critical backbone of the U.S. medical device supply chain, helping ensure consistent access to high-quality medical devices nationwide.
